secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001140361-25-001013
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics initiates $40M ATM equity offering with Leerink Partners
----------------------------------------------------------------------

- Entered into ATM equity sales agreement with Leerink Partners LLC for up to $40M in common stock.
- Prior ATM program with JonesTrading terminated; $26.4M had been sold under that program.
- Net proceeds for general corporate purposes, including preclinical studies and clinical trials.
- Leerink receives 3% commission on gross sales; Company has broad discretion over proceeds use.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125001013/0001140361-25-001013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125001013/ny20040461x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-001013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer